IBIO iBio Forecast, Technical & Fundamental Analysis
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies... Show more
IBIO is expected to report earnings to fall 8.86% to -6 cents per share on September 29
Q2'26
Est.
$-0.06
Q1'26
Beat
by $0.13
Q4'25
Beat
by $0.34
Q3'25
Beat
by $0.14
Q2'25
Missed
by $0.12
The last earnings report on May 12 showed earnings per share of -7 cents, beating the estimate of -20 cents. With 571.01K shares outstanding, the current market capitalization sits at 72.78M.
A.I. Advisor
published General Information
General Information
a company which engages in the development and commercialization of vaccines and therapeutic proteins
A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.
IBIO in downward trend: price dove below 50-day moving average on July 02, 2026
IBIO moved below its 50-day moving average on July 02, 2026 date and that indicates a change from an upward trend to a downward trend. In of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBIO as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IBIO turned negative on July 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for IBIO crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for IBIO moved below the 200-day moving average on June 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .
IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.939) is normal, around the industry mean (22.885). P/E Ratio (0.654) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). IBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (344.828) is also within normal values, averaging (434.181).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
